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Human multipotent adult progenitor cells (hMAPCs) are isolated from bone marrow with a more extensive 
expansion capacity compared to human mesenchymal stem cells (hMSCs) and with the ability to differentiate 
into endothelium. Like hMSCs, hMAPCs inhibit T-cell proliferation induced by alloantigens. In this study, we 
tested the interaction between hMAPCs and natural killer (NK) cells. We assessed the susceptibility of hMAPCs 
to NK cell-mediated lysis and the immunomodulation of hMAPCs on NK cell function during IL-2-driven stim-
ulation and the cytolytic effector phase. Human MAPCs express the ligands PVR and ULBP-2/5/6, which are 
recognized by activating NK cell receptors. However, they also express MHC class I molecules, which induce 
inhibitory signals in NK cells. Freshly isolated NK cells at different effector:target ratios did not kill hMAPCs 
as assessed by an MTT and 51Cr-release assay, while hMAPCs impaired the cytotoxic activity of resting NK 
cells against the NK-sensitive K562 leukemia cell line. By contrast, IL-2-stimulated NK cells were capable 
of killing hMAPCs, and preactivated NK cells were not influenced during their cytotoxic effector function 
against K562 cells by hMAPCs. When added during the 6-day preactivation phase with IL-2, hMAPCs dose-
 dependently reduced NK cell proliferation in an IDO-dependent manner, but they did not influence the induc-
tion of cytotoxic capacity by IL-2. This study indicates that human MAPCs mutually interact with NK cells.
Key words: Human multipotent adult progenitor cells (hMAPCs); Natural killer (NK) cells;  
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INTRODUCTION
Stem cell-based therapy has become a promising tool 
to control immune responses. In the past decade, human 
mesenchymal stem cells (hMSCs) have been studied for 
their role as a cellular immunosuppressive cell population 
(25,26). MSCs are bone marrow-derived cells, which are 
capable of differentiating into chondrocytes, osteoblasts, 
and adipocytes (5,7). Clinical trials wherein hMSCs are 
infused intravenously are currently under way to evalu-
ate their ability to prevent or suppress graft-versus-host 
disease (GvHD) in patients who underwent hematopoi-
etic stem cell transplantation or to treat autoimmune dis-
eases (11,12). The results of phase I and II clinical trials 
have demonstrated the feasibility and safety of in vivo 
use of these cells. The rationale for the use of hMSCs as 
an immunosuppressive cell population is based on a large 
number of studies that have shown that hMSCs inhibit 
T-cell responses in vitro (1,4,10,13), aside from affecting 
B-cells (2), dendritic cells (9,17), and natural killer (NK) 
cells in vitro (22–24).
NK cells are part of the innate immune system and 
play a key role in the immune defense against viral infec-
tions and in antitumor immune responses, based on their 
cytolytic function and production of proinflammatory 
cytokines. NK cell function is regulated by the balance 
between activating and inhibiting signals transduced by 
multiple cell surface receptors on NK cells (15). NK cell-
mediated killing of a target cell requires the presence 
of activating ligands on the target cell interacting with 
activating receptors on the NK cells in combination with 
low or absent levels of major histocompatibility complex 
(MHC) class I molecules on the target cell, as the latter 
stimulate inhibitory receptors (14,16). MSCs are known 
to express high levels of MHC class I molecules (21). 
Both autologous and allogeneic MSCs can be lysed by 
activated NK cells. On the other hand, MSCs themselves 
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can inhibit the cytotoxic activity and proliferation of NK 
cells (22–24).
Human multipotent adult progenitor cells (hMAPCs) 
are also bone marrow-derived stem cells (21). Compared 
with hMSCs, hMAPCs can be expanded more extensively 
than hMSCs. In addition, hMAPCs express lower lev-
els of MHC class I molecules and differentiate robustly 
into endothelium both in vitro and in vivo in Matrigel 
plug assays. Like hMSCs, hMAPCs suppress allogeneic 
T-cell responses in vitro and block ongoing and second-
ary allogeneic T-cell responses and responses of memory 
T-cells (8). Their immunosuppressive potency, combined 
with their extensive proliferation potential, means that 
hMAPCs are a preferable alternative source for cell-
based immunotherapy because a large cohort of patients 
can be treated with one single and well-defined batch of 
cells. Clinical trials with MultiStemÒ, the clinical-grade 
product of MAPCs, are being performed to test their 
ability to prevent acute GvHD, treat inflammatory bowel 
disease (IBD), and prevent rejection of liver grafts, aside 
from evaluating their ability to improve cardiac and neu-
ral function, when administered in the setting of acute 
myocardial infarction and stroke (www.ClinicalTrials.
gov).
No systematic studies have been performed to address 
the interaction between hMAPCs and NK cells, so we 
here describe the NK cell function in the presence of 
hMAPCs and the hMAPC-mediated modulation of NK 
cell function during the interleukin (IL)-2-driven stimula-
tion and cytolytic effector phase of NK cells.
MATERIALS AND METHODS
Isolation and Culture of Stem Cells
hMAPC (n = 6) isolations were done by the Stem Cell 
Institute Leuven (SCIL, Leuven, Belgium) from bone 
fragments of four children (two male and two female 
between 5 and 15 years old; donors 1–4) undergoing 
orthopedic surgery or by ReGenesys (www.regenesys.eu; 
Heverlee, Belgium) from the bone marrow of two healthy 
volunteers [a 45-year-old male (donor 5) and a 30-year-
old female (donor 6)], after obtaining informed consent 
in accordance with the guidelines of the Medical Ethics 
Committee of the University Hospitals Leuven. Isolation 
and culture of the cells were performed as previously 
described (20). Briefly, hMAPCs were generated by plat-
ing the total cell fraction at 0.5 × 106 cells/cm2 in medium 
consisting of 60% Dulbecco’s modified Eagle’s medium 
(DMEM) low-glucose (Gibco, Invitrogen, Carlsbad, CA, 
USA), 40% MCDB-201 (Sigma-Aldrich, St. Louis, MO, 
USA), supplemented with 50 nM dexamethasone, 10−4 M 
l-ascorbic acid, 1× insulin–transferrin–selenium (ITS), 
0.5× linoleic acid–bovine serum albumin (LA-BSA) 
(all from Sigma-Aldrich), 1% penicillin/streptomycin 
(Gibco, Invitrogen), along with 2% Serum Supreme 
(Lonza BioWhittaker, Basel, Switzerland) and 10 ng/
ml human platelet-derived growth factor (PDGF)-BB 
(R&D Systems, Minneapolis, MN, USA) and epidermal 
growth factor (EGF) (Sigma-Aldrich). MAPC cultures 
were maintained under hypoxic conditions (5% O2) at a 
density of 400 cells/cm2 and were split every 2 to 3 days. 
Clonal populations of hMAPCs isolated by SCIL were 
obtained through limiting dilution by plating five cells/
well in a 96-well or 48-well plate (Corning, Corning, NY, 
USA) between passages 5 to 10. In some experiments, 
hMAPCs were treated with 100 U/ml interferon (IFN)-g 
(Roche Diagnostics, Vilvoorde, Belgium) for 48 h.
Human MSCs were generated by ReGenesys from the 
bone marrow of the two adult hMAPC donors (donors 5 
and 6) by plating the mononuclear fraction, obtained after 
LymphoprepTM (Axis-Shield, Oslo, Norway) density gra-
dient centrifugation, at 0.5 × 106 cells/cm² in MSC growth 
medium containing DMEM high-glucose, 10% fetal calf 
serum (FCS), 100 IU/ml penicillin, and 100 µg/ml strep-
tomycin (all from Lonza). MSC cultures were maintained 
at 5,000 cells/cm², at normal oxygen level (20% O2), were 
split every 4 to 7 days, and were not clonally derived.
Isolation and Culture of Peripheral Blood 
Mononuclear Cells and NK Cells
All subjects donating blood for these experiments were 
healthy volunteers of both sexes, aged 20 to 50 years. 
Peripheral blood mononuclear cells (PBMCs) were sepa-
rated by Ficoll-Hypaque (Axis-Shield) density gradient 
centrifugation (specific gravity, 1.077 g/ml). Untouched 
NK cells were negatively selected from PBMCs using the 
human NK cell isolation kit (Miltenyi Biotec, Bergisch 
Gladbach, Germany) according to the manufacturer’s 
instructions. Purity ranged from 88% to 98%.
To obtain activated NK cells, PBMCs or purified NK 
cells were cultured for 6 days in Roswell Park Memorial 
Institute (RPMI) 1640 medium with 2 mmol/L l-glutamine, 
100 U/ml penicillin, 100 µg/ml streptomycin (all Lonza), 
and 10% autologous serum supplemented with 100 U/ml 
recombinant human IL-2 (TECIN; Hoffmann-La Roche, 
Nutley, NJ, USA) in T25 culture flasks (Greiner Bio-One, 
Wemmel, Belgium). PBMCs were cultured at 10 × 106 
cells in 10 ml, while purified NK cells were cultured at 1 
to 3 × 106 cells in 10 ml. To these cultures, nonirradiated 
hMAPCs were added in a ratio of 1:3 PBMCs or purified 
NK cells.
Flow Cytometry
hMAPCs, cultured PBMCs, or NK cells (1 × 105 for 
each) per sample were suspended in 100 µl phosphate-
buffered saline (PBS; Lonza) supplemented with 10% 
heat- inactivated human serum (Lonza) to block nonspecific 
staining. Cells were subsequently surface stained with 5 µl 
fluorescence-conjugated specific monoclonal antibodies. 
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The specifications of the antibodies used for flow cytom-
etry are described in Table 1. Isotype control staining was 
performed. Acquisition was done using a FACSort or 
FACSCanto (BD Biosciences, Erembodegem, Belgium). 
For analysis of the samples, CellQuest Pro or BD 
FACSDiva software was used.
Cytotoxicity Assays
The viability of hMAPC target cells was tested with 
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT, Sigma, Bornem, Belgium) assay as pre-
viously described with some modifications (3). Briefly, 
target cells were seeded in a flat-bottomed 96-well cell 
culture plate (TPP, St. Louis, MO, USA) at a density of 
5 × 104 cells/well and cultured overnight to become adher-
ent to the plate. The next day, NK cells were added at 
different effector:target (E:T) ratios and cocultured for 
24 h, after which the medium, together with the nonad-
herent cells, was removed. Subsequently, the target cells 
were rinsed with PBS at room temperature, and 100 µl 
of a 0.5 mg/ml MTT solution was added to the residual 
adherent cells. After 2 h of incubation, the MTT solu-
tion was removed, and 100 µl dimethyl sulfoxide (Merck, 
Darmstadt, Germany) per well was added to resolve the 
formazan produced in the viable cells. After stirring the 
plate for 5 min, optical density was measured at 570 and 
620 nm using an ELISA reader (Thermo Labsystems, 
Franklin, MA, USA). The OD570–620 nm value was used as a 
measure for cell viability.
Cytotoxicity assays were also performed using a 
4-h 51Cr-release method. Target cells were labeled with 
100 µCi 51Cr/106 cells (51Cr, Perkin Elmer Life Sciences, 
Inc., Zaventem, Belgium) and seeded at 104 cells/well in 
round-bottomed 96-well plates (Greiner Bio-One). As con-
trol target cells, the human NK-sensitive and MHC class 
I-deficient K562 leukemia cell line was used (ATCC, 
Manassas, VA, USA). The lytic potential of NK cells was 
tested by coculturing cells at different E:T ratios. Saponin 
(Merck) was added to the target cells to measure the max-
imum release of 51Cr. Release of 51Cr was measured by a 
Topcount gamma counter (Packard Instrument Company, 
Meriden, CT, USA). The percentage cytotoxicity was cal-
culated as [(experimental release − spontaneous release)/
(maximal release − spontaneous release)]  ×  100.
To test the influence of hMAPCs during the lytic func-
tioning of NK cells against K562 cells, nonirradiated 
hMAPCs were added at 1:2 ratio MAPC:NK at the begin-
ning of the 4-h assay. We used the NK-resistant human 
cell line KM-H2 (Hodgkin disease-derived cell line; 
kindly provided by Dr. S. Fukuhara, Kyoto University, 
Kyoto, Japan) as control cells for hMAPCs in this assay.
Proliferation Assay
Responder purified NK cells (1 × 105) were stimulated 
with 100 U/ml exogenous recombinant IL-2 (TECIN; 
Hoffmann-La Roche). Irradiated (30 Gy) allogeneic 
hMAPCs were added at different suppressor:responder 
(S:R) ratios. NK cell proliferation was measured at day 6 
by means of an 8-h pulse with 1 µCi/well [3H]thymidine 
(MP Biomedicals Europe, Illkirch, France). [3H]Thymidine 
incorporation was measured by using a liquid scintilla-
tion counter (Tri-Carb® 2100TR Liquid Scintillation 
Counter, PerkinElmer). The data were analyzed as mean 
counts per minute (cpm) of quadruplicate wells. The results 
Table 1. List of Monoclonal Antibodies Used for Flow Cytometry
Monoclonal Ab Supplier (Catalog No.) Label Isotype
CD3 BD Pharmingen (Erembodegem, Belgium; 
555332) 
FITC IgG1
CD56 BD Biosciences (Erembodegem, Belgium; 
345810) 
PE IgG1
CD3/CD16+CD56 BD Simultest (342403) FITC/PE IgG1
HLA-ABC BD Pharmingen (555552) FITC IgG1
HLA-E eBioscience (Vienna, Austria; 12-9953) PE IgG1
Nectin-2 (CD112) BD Pharmingen (551057) PE IgG1
PVR (CD155) eBioscience (12-1550) PE IgG1
MICA/B BD Pharmingen (558352) PE IgG2a
ULBP-1 R&D Systems (Abingdon, UK; FAB1380P) PE IgG2a
ULBP-2/5/6 R&D Systems (FAB1298P) PE IgG2a
ULBP-3 R&D Systems (FAB1517P) PE IgG2a
IgG1 BD Biosciences (345815) FITC 
IgG1 BD Biosciences (345816) PE 
IgG2a BD Pharmingen (555574) PE
CD, cluster of differentiation; HLA, human leukocyte antigen; PVR, poliovirus receptor; MICA/B, major histo-
compatibility complex (MHC) class I chain-related genes A and B; ULBP, UL16-binding protein; Ig, immuno-
globulin; FITC, fluorescein isothiocyanate; PE, phycoerythrin.
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are expressed as percent response related to the control 
response in the absence of hMAPCs.
To analyze the involvement of indoleamine 2,3-diox-
ygenase (IDO), prostaglandin E2 (PGE2), transforming 
growth factor (TGF)-b, and IL-10 as immunosuppressive 
mediators, we used their respective inhibitors: 200 µM/
ml 1-methyl-tryptophan (1-MT; Sigma-Aldrich); 2 µg/
ml indomethacin (Cayman Chemical Company, Ann 
Arbor, MI, USA), 50 µg/ml anti-TGF-b neutralizing 
mAb (R&D Systems, Abingdon, UK), and 2.5 µg/ml 
anti-IL-10 plus 2.5 µg/ml anti-IL-10 receptor mAb (both 
from R&D Systems).
Statistical Analysis
Statistics were calculated with Prism software 5.0 
(GraphPad Software, Inc., San Diego, CA, USA). 
Statistical significance was calculated by paired or 
unpaired t tests for comparisons between two groups 
and by one-way ANOVA with Dunnett’s post hoc test 
for comparisons between three or more groups. Values of 
p < 0.05 were considered significant.
RESULTS
Human MAPCs Express Ligands of 
Activating NK Receptors
To assess whether hMAPCs might be susceptible for 
NK cell-mediated lysis, we first analyzed hMAPCs for 
the expression of ligands recognized by activating and 
inhibitory NK cell receptors. Table 2 shows the expres-
sion level of ligands of NK cell receptor D (NKG2D) 
[UL16-binding proteins (ULBPs) and MHC class I 
chain-related genes A and B (MICA/B)] and DNAX 
accessory molecule-1 [DNAM-1; cluster of differen-
tiation 226 (CD226)] [Nectin-2 and poliovirus receptor 
(PVR; CD155)] triggering receptors and of inhibitory 
MHC class I molecules (HLA-ABC and nonclassic 
HLA-E) in five hMAPC populations (donors 1–5). Flow 
cytometric analysis showed that all hMAPC populations 
are dimly positive for HLA-ABC [mean fluorescence 
intensity (MFI) ± SEM for the five hMAPC popula-
tions: 1,992 ± 246] and negative for HLA-E. hMAPCs 
expressed PVR (8,540 ± 150) and low levels of ULBP-
2/5/6 (1,173 ± 123), but generally did not express 
MICA/B, Nectin-2, ULBP-1, and ULBP-3. Upon stimu-
lation with IFN-g, expression of MHC class I molecules 
was upregulated, whereas the expression of the activat-
ing ligands remained unchanged.
Resting NK Cells Do Not Kill hMAPCs But Are Blocked 
in Their Cytolytic Function by hMAPCs
The combination of expression of ligands of activating 
NK cell receptors together with low levels of MHC class I 
molecules on hMAPCs suggests that hMAPC target cells 
might be killed by allogeneic NK cells. To investigate 
whether hMAPCs are susceptible to NK cell-mediated 
lysis, freshly isolated NK cells were cocultured with allo-
geneic hMAPCs at E:T ratios of 1:1 to 8:1 during 24 h. 
Coculture was followed by an assessment of hMAPC 
viability using the MTT assay. Human MAPCs were not 
killed by resting allogeneic NK cells (Fig. 1A). We con-
firmed these findings using a chromium release assay. 
This revealed that hMAPCs were only minimally lysed 
by resting allogeneic NK cells even at higher E:T ratios 
(Fig. 1B). Subsequently, to investigate whether hMAPCs 
Table 2. NK Cell Receptor Ligand Expression by hMAPCs
Donor
1 2 3 4 5
Marker − + − + − + − + − +
Bare cells FITC 336 266 276 309 443 506 245 301 391 416
Bare cells PE 212 189 170 187 270 311 154 188 241 265
Isotype IgG1 FITC 368 402 330 333 534 560 251 325 439 473
Isotype IgG1 PE 455 481 403 474 537 615 348 413 555 594
Isotype IgG2a PE 238 233 194 200 264 307 246 266 346 358
HLA-ABC FITC 1,826 12,737 3,470 13,363 1,843 7,469 1,440 8,488 1,381 10,134
HLA-E PE 619 2,189 900 2,450 640 1,569 486 1,850 708 2,230
MICA/B PE 250 262 583 760 329 344 461 423 346 544
Nectin-2 PE 175 229 368 380 656 598 309 411 208 243
PVR PE 8,114 8,580 8,137 8,074 9,269 9,736 8,907 10,428 8,275 8,497
ULBP-1 PE 381 370 1,023 982 399 369 423 468 616 666
ULBP-2/5/6 PE 756 710 1,263 1,093 867 890 1,137 1,114 1,844 1,831
ULBP-3 PE 247 239 305 325 238 292 258 275 404 330
Flow cytometric analysis of five human multipotent adult progenitor cell (hMAPC) donors (donors 1–5) for ligands of inhibitory (HLA-ABC and 
HLA-E) and activating natural killer (NK) cell receptors (MICA/B, Nectin-2, PVR, ULBP-1, ULBP-2/5/6, and ULBP-3) before and after treatment 
with 100 U/ml interferon (IFN)-g for 48 h. Results are expressed as mean fluorescence intensity (MFI). −, without IFN-g pretreatment; +, with IFN-g 
pretreatment.
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could interfere with the effector function of resting NK 
cells, we added hMAPCs at the beginning of a 51Cr-
 release assay of freshly isolated NK cells against K562 
target cells. As shown in Figure 2A, hMAPCs impaired 
the cytotoxic activity of resting NK cells (mean ± SEM% 
51Cr-release: 44.81 ± 4.97% vs. 60.32 ± 3.40%). To exclude 
the possibility of “cold target inhibition” by hMAPCs, the 
NK-resistant cell line KM-H2 was used as a modulating 
cell line instead of hMAPCs. The resistance of KM-H2 
cells to NK cell-mediated killing was verified (data not 
shown). Addition of KM-H2 cells at the beginning of a 
51Cr-release assay of freshly isolated NK cells against 
K562 target cells did not significantly influence the cyto-
toxic activity of the NK cells, in contrast to hMAPCs 
(Fig. 2B).
Figure 1. Human MAPCs are not killed by resting NK cells. 
(A) Freshly isolated natural killer (NK) cells (n = 3) were cocul-
tured with allogeneic human multipotent adult progenitor cell 
(hMAPC) target cells (n = 2; donors 5 and 6) at effector:target 
(E:T) ratios of 1:1 to 8:1 during 24 h. Coculture was followed 
by an assessment of hMAPC viability using the 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Data 
are expressed as percentage (mean ± SEM) of target cell viabil-
ity (optical density) with respect to target cell viability with-
out coincubation of NK cells (100%). Statistical significance 
was tested when compared with control condition without NK 
cells. One-way ANOVA with Dunnett’s post hoc test was used, 
ns = not significant. (B) Freshly isolated NK cells were cocul-
tured in a standard 51Cr-release assay with K562 cells or alloge-
neic hMAPCs at different E:T ratios of 50:1 to 25:1. Data are 
expressed as mean ± SEM percentage 51 Cr-release of four dif-
ferent experiments with four different NK cell donors and three 
different hMAPC donors (donors 1, 5, 6).
Figure 2. Impaired cytotoxic activity of resting NK cells in 
the presence of hMAPCs. (A) Results of cytotoxic activity of 
freshly isolated NK cells against K562 target cells (E:T 25:1) 
in the absence (control) or presence (+hMAPCs) of allogeneic 
hMAPCs at suppressor:responder (S:R) ratio of 1:2. Results 
are expressed as mean ± SEM percentage 51Cr-release of 10 
experiments, in which six different NK cell donors and two dif-
ferent hMAPC donors (donors 5 and 6) were used. Statistical 
significance was calculated with the paired t test. **p < 0.01. 
(B) Results of cytotoxic activity of freshly isolated NK cells 
against K562 target cells (E:T 25:1) in the absence (control) or 
presence of allogeneic hMAPCs (+hMAPCs) or NK-resistant 
KM-H2 cells (+KM-H2) at S:R ratio of 1:2. Results are expressed 
as mean ± SEM percentage 51Cr-release of four experiments, in 
which four different NK cell donors and two different hMAPC 
donors (donors 5 and 6) were used. Statistical significance was 
calculated with ANOVA and Dunnett’s post hoc test. ns, not sig-
nificant, *p < 0.05.
1104 JACOBS ET AL.
Activated NK Cells Lyse Allogeneic hMAPCs
The adoptive transfer of hMAPCs is aimed at control-
ling immune responses. The local inflammatory envi-
ronment wherein hMAPCs reside upon injection will 
probably lead to activation of the regional NK cell popu-
lation. To address the interaction between activated NK 
cells and allogeneic hMAPCs, we activated NK cells with 
rIL-2 for 6 days and tested their ability to kill allogeneic 
hMAPC target cells. The MTT viability assay revealed 
that preactivated NK cells were capable of killing allo-
geneic hMAPCs (Fig. 3A). We confirmed these findings 
using a chromium release assay, showing that the chro-
mium release of hMAPCs as target cells for activated 
NK cells was similar to the control condition using K562 
cells (Fig. 3B), indicating that hMAPCs can be killed by 
activated NK cells. However, pretreatment of hMAPCs 
with 100 U/ml IFN-g for 48 h, leading to an upregulation 
of HLA-ABC and HLA-E expression (Table 2), rendered 
those IFN-g-pretreated hMAPCs resistant to cytotoxic 
lysis by activated NK cells (6.59 ± 2.80% 51Cr release vs. 
21.29 ± 5.55% 51Cr release) (Fig. 3C).
In addition, we tested the ability of hMAPCs to influ-
ence the cytotoxic function of activated NK cells during 
their effector phase. Therefore, a standard 51Cr-release 
assay was performed using NK cells that were cultured 
for 6 days in the presence of 100 U/ml rIL-2, and cyto-
toxic activity against K562 target cells was tested at an 
E:T ratio of 25:1 in the presence or absence of allogeneic 
FACING COLUMN
Figure 3. Human MAPCs are killed by activated NK cells. 
(A) NK cell populations (n = 2) that were exposed to 100 U/ml 
recombinant interleukin (rIL)-2 for 6 days were cocultured 
with allogeneic hMAPC (n = 2; donors 5 and 6) target cells at 
E:T ratios of 1:1 to 8:1. Coculture for 24 h was followed by 
an assessment of hMAPC viability using the MTT assay. Data 
are expressed as percentage (mean ± SEM) of target cell viabil-
ity (optical density) with respect to target cell viability with-
out coincubation of NK cells (100%). Statistical significance 
was tested when compared with control condition without NK 
cells. One-way ANOVA with Dunnett’s post hoc test was used, 
***p < 0.001, **p < 0.01. (B) Cytotoxic activity measured by 
51Cr-release assay of freshly isolated NK cells (resting NK cells) 
and NK cell populations cultured for 6 days with rIL-2 (activated 
NK cells) against K562 or allogeneic hMAPC target cells at an 
E:T ratio of 25:1. Data are expressed as mean ± SEM percentage 
51Cr-release of five different experiments with three different 
NK cell donors and three different hMAPC donors (donors 1, 
5, 6). (C) Cytotoxic activity measured by 51Cr-release assay of 
activated NK cell populations cultured for 6 days with rIL-2, 
coincubated with allogeneic hMAPCs or interferon (IFN)-g pre-
treated hMAPCs at an E:T ratio of 25:1. Data are expressed 
as mean ± SEM percentage 51Cr release of five different experi-
ments with three different NK cell donors and three different 
hMAPC donors (donors 1, 5, 6). Statistical significance was 
calculated with the unpaired t test, *p < 0.05.
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hMAPCs (ratio hMAPC:NK cell 1:2). We noticed that 
the presence of hMAPCs reduced the percentage of 51Cr 
release (41.60 ± 3.12%) compared to the conditions cul-
tured in the absence of hMAPCs (64.80 ± 4.17%) (Fig. 4). 
However, because activated NK cells have been shown 
to kill hMAPCs as well, we could not exclude that the 
reduction in 51Cr release was due to competition between 
hMAPCs and K562 cells as both cell populations are 
known target cells for the activated NK cells. To test this 
hypothesis, a 51Cr-release assay was performed using 
rIL-2 activated NK cells against K562 cells (E:T 25:1) in 
the presence or absence of extra unlabeled or 5ICr-labeled 
K562 cells or hMAPCs (both 1:2 ratio to NK cells). In 
comparison to the control condition, the percentage 51Cr 
release decreased with extra addition of unlabeled K562 
cells or hMAPCs, while the percentage clearly increased 
with extra addition of labeled K562 cells or hMAPCs 
(data not shown). Addition of supernatant of cultured 
hMAPCs did not influence the cytotoxic function of rIL-2-
activated NK cells. These observations imply a cold tar-
get inhibition effect.
Human MAPCs Inhibit IL-2-Induced Proliferation of 
Allogeneic NK Cells in an IDO-Dependent Manner
We finally assessed whether hMAPCs have a simi-
lar suppressive effect on NK cell proliferation as they 
have on T-cell proliferation. NK cells were stimulated 
with rIL-2 (100 U/ml) in the presence or absence of 
irradiated allogeneic hMAPCs at different S:R ratios 
and evaluated with [3H]thymidine incorporation after 
6 days. As shown in Figure 5A, human MAPCs dose-
dependently suppressed IL-2-induced proliferation of 
highly purified NK cells. The expansion of NK cells 
(defined as % CD3−CD56+ cells) was also blocked when 
total PBMC fractions were cultured in medium supple-
mented with exogenous rIL-2 for 6 days in the presence 
of hMAPCs (10.64 ± 2.77% CD3−CD56+ cells) com-
pared to similar cultures of PBMCs in the absence of 
hMAPCs (37.57 ± 3.59% CD3−CD56+ cells) (Fig. 5B). Of 
note, in this set of experiments, hMSCs from the same 
donor as the hMAPCs were available. The decrease in 
the expansion of NK cells was less pronounced when 
PBMCs were activated with rIL-2 in the presence of 
hMSCs (22.70 ± 8.76% CD3−CD56+ cells), compared to 
the condition with hMAPCs.
The immune modulatory mechanism of hMAPCs is 
mediated at least in part via a soluble factor (8), so we per-
formed some functional tests to identify the responsible 
mediator. Blocking IDO with 1-MT completely neutral-
ized the inhibitory activity of hMAPCs on IL-2-induced 
NK cell proliferation, suggesting IDO as a mediator of 
the immune modulation by hMAPCs (Fig. 6). Addition 
of monoclonal antibodies neutralizing IL-10 plus IL-10R, 
or monoclonal antibodies to neutralize TGF-b, or addi-
tion of indomethacin to neutralize PGE2 synthesis did not 
change the immunomodulatory properties of hMAPCs on 
IL-2-induced NK cell proliferation. None of these mol-
ecules mediated the immune modulatory role of hMAPCs 
on the cytotoxic activity of resting NK cells against K562 
cells (data not shown).
In the next set of experiments, total PBMC fractions 
were cultured for 6 days with rIL-2 in the presence or 
absence of nonirradiated hMAPCs, and the cytolytic func-
tion of the NK cells was subsequently measured against 
K562 cells. As shown in Figure 7A, the lytic activity was 
strongly diminished when the whole PBMC population 
was stimulated with rIL-2 in the presence of hMAPCs 
compared to the control condition without hMAPCs. 
We did not see any influence on the cytotoxic activity 
of the NK cells when PBMCs were activated with rIL-2 
in the presence of hMSCs from the same hMAPC donors. 
The cytolytic activity in these experiments was influenced 
by the inhibition of NK cell proliferation, thereby influ-
encing the net E:T ratio during the subsequent effector 
phase, so similar experiments were performed with puri-
fied NK cells as responder and effector cells. After stimu-
lation of purified NK cells with rIL-2 in the presence of 
nonirradiated hMAPCs, the cells were adjusted prior to 
the cytotoxicity assay. In this condition, we could demon-
strate that the cytolytic function of NK cells was retained 
after rIL-2 activation in the presence of hMAPCs, in spite 
of the blocked proliferative response (Fig. 7B). Of note, 
addition of irradiated hMAPCs in this experimental con-
dition yielded similar results (data not shown).
Figure 4. Impaired cytotoxic activity of activated NK cells 
in the presence of hMAPCs. Results of cytotoxic activity of 
rIL-2-activated NK cells against K562 target cells (E:T 25:1) 
in the absence (control) or presence (+hMAPCs) of allogeneic 
hMAPCs at S:R of 1:2. Results are expressed as mean ± SEM 
percentage 51Cr release of four experiments, in which two dif-
ferent NK cell donors and two different hMAPC donors (donors 
5 and 6) were used. Statistical significance was calculated with 
the paired t test. ***p < 0.001.
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DISCUSSION
In the present study, we report on the interaction 
between hMAPCs and NK cells. Resting NK cells do not 
kill hMAPCs and are blocked in their cytolytic function 
by hMAPCs. hMAPCs block IL-2-induced NK cell pro-
liferation but not their subsequent effector function. On 
the other hand, activated NK cells kill hMAPCs, unless 
the latter were preincubated with IFN-g and are no longer 
blocked by hMAPCs during their cytotoxic functioning. 
Hence, there is a balance in the mutual interaction between 
hMAPCs and NK cells depending on the activation state 
of the NK cells and the priming of hMAPCs.
Our data on the NK cell susceptibility of allogeneic 
hMAPCs are in accordance with published reports on 
hMSCs (18,22,24). hMAPCs express lower levels of 
MHC class I molecules compared to hMSCs (8,21), and 
also express ligands for activating NK cell receptors on 
its surface. To trigger a NK cell, failure to recognize 
appropriate inhibitory ligands on a target cell is man-
datory. MSCs express high levels of MHC class I mol-
ecules, so it was hypothesized that MSCs would escape 
NK cell-mediated lysis. Indeed, published data showed 
that MSCs resist lysis of alloreactive resting NK cells. 
However, activated NK cells are capable of killing allo-
geneic and autologous MSCs (6,22,24). The data sug-
gest that the interaction between MHC class I-specific 
inhibitory receptors on NK cells and the MHC class I 
molecules on the MSCs is not sufficient to protect MSCs 
from lysis. The susceptibility of hMAPCs for activated 
NK cells may hamper their survival in vivo. hMAPCs 
will be used as an off-the-shelf stem cell product and will 
be consequently of third-party origin; it can therefore be 
hypothesized that in an inflammatory environment, which 
is the situation in the case of GvHD or ischemia, nearly 
all hMAPCs will be killed. This however might, at least 
in part, be counteracted by the inflammation-induced 
upregulation of MHC class I molecules on hMAPCs. 
Indeed, for hMSCs, Spaggiari et al. reported that the 
upregulation of MHC class I molecules on hMSCs due 
to stimulation with IFN-g rendered these cells resistant to 
NK cell-mediated lysis (24). We were able to document 
similar results for hMAPCs. Based on these findings, we 
can hypothesize that the final outcome of the interaction 
between hMAPCs and NK cells in vivo will depend on 
the local inflammatory environment.
The presence of hMAPCs impaired the cytolytic 
potential of resting NK cells in vitro. hMAPCs were not 
killed by resting NK cells, so the reduced cytotoxic effect 
of resting NK cells in the presence of hMAPCs was not 
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Figure 5. hMAPCs dose dependently suppress IL-2-induced NK cell proliferation. (A) Freshly isolated NK cells were cultured during 
6 days in medium supplemented with 100 U/ml rIL-2 in the absence or presence of allogeneic irradiated (30 Gy) hMAPCs at different 
S:R ratios. The proliferative response was measured on day 6 by [3H]thymidine incorporation. Results are expressed as mean ± SEM 
percentage proliferation relative to control cultures in the absence of hMAPCs of six experiments in which five different NK cell 
donors and three different hMAPC donors (donors 1, 5, 6) were used. Statistical significance was calculated with one-way ANOVA 
with Dunnett’s post hoc test, **p < 0.01, *p < 0.05. (B) Total peripheral blood cell (PBMC) fractions were cultured in medium supple-
mented with exogenous rIL-2 for 6 days in the absence (upper left) or presence of human mesenchymal stem cells (hMSCs; upper 
right) or hMAPCs (lower left) from the same donor at S:R ratio of 1:3. The expansion of NK cells [percentage cluster of differentia-
tion 3 negative cluster of differentiation 56 positive (CD3−CD56+) cells] in the total PBMC fraction was afterwards analyzed by flow 
cytometry. One out of three representative experiments is shown in the flow cytometry plots. In the bar graph (lower right), results 
from three different experiments with three different PBMC donors and two hMSC/hMAPC donors (donors 5 and 6) were pooled and 
expressed as mean ± SEM percentage CD3−CD56+ cells. Statistical significance was calculated with one-way ANOVA with Dunnett’s 
post hoc test, ns = not significant, *p < 0.05.
Figure 6. The suppressive effect of hMAPCs on NK cell pro-
liferation is dependent on IDO activity. Freshly isolated NK 
cells were cultured during 6 days in medium supplemented 
with 100 U/ml rIL-2 in the absence or presence of irradiated 
hMAPCs at S:R ratio of 1:2 without (control) or with addi-
tion of 2 µg/ml indomethacin, 200 µM/ml 1-methyl tryptophan 
(1-MT), 2.5 µg/ml anti-IL-10 plus 2.5 µg/ml anti-IL-10 receptor 
(R) mAb, or 50 µg/ml anti-transforming growth factor (TGF)-b 
neutralizing mAb. The proliferative response was measured on 
day 6 by [3H]thymidine incorporation. Data are expressed as 
mean ± SEM percentage proliferation relative to control cul-
tures in the absence of hMAPCs of three experiments in which 
two NK cell donors and two hMAPC donors (donors 5 and 6) 
were used. The average counts per minute (cpm) of the cultures 
without hMAPCs for all conditions were all similar to the con-
trol condition without hMAPCs (average cpm: 13,855). IDO, 
indoleamine 2,3-dioxygenase.
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due to competition of target cells. We confirmed this 
hypothesis by using NK-resistant KM-H2 cells instead of 
hMAPCs as modulating cells in some experiments. The 
question whether hMAPCs were able to block the cyto-
toxic function of rIL-2-activated NK cells could not be 
answered in our experiments, as activated NK cells were 
killing both the K562 target cells and hMAPCs.
hMAPCs suppressed rIL-2-induced proliferation of 
NK cells during stimulation with rIL-2 for 6 days but 
not their cytotoxic function. The mechanism respon-
sible for the immunosuppression of hMAPCs is not yet 
completely understood. Several candidate molecules 
have been proposed as the soluble immunosuppressive 
factor produced by hMSCs, although data are contradic-
tory because of different experimental designs to study 
immunosuppression (1,4,13,19). In our hands, blockage 
of TGF-b, IL-10, or PGE2 synthesis did not influence the 
suppressive effect of human MAPCs on rIL-2-induced 
NK cell proliferation. Addition of 1-MT to cocultures 
of freshly isolated NK cells with hMAPCs resulted in a 
loss of the hMAPC-mediated suppressive effect on IL-2-
mediated NK cell proliferation, confirming the role of 
IDO as one of the responsible mediators. None of these 
mediators was responsible for the modulation during the 
cytotoxic effector phase of resting NK cells. Our data are 
in accordance with previously published results on T-cell 
alloreactivity (8).
The present study was primarily aimed to study the 
mutual interaction between hMAPCs and NK cells. Related 
to sensitivity to NK cell-mediated killing, modulation 
Figure 7. Suppression of NK cells by hMAPCs during activation with rIL-2. (A) After 6-day culture with rIL-2 in the presence or 
absence of hMAPCs or hMSCs (S:R ratio of 1:3) during the activation phase, the total PBMC fraction was subsequently cocultured 
with K562 leukemia cell line at E:T ratios of 50:1 and 25:1 during the effector phase. Specific K562 lysis was measured with 51Cr 
release. Data are expressed as mean percentage 51Cr release of three independent experiments using three different PBMC donors 
and two different hMAPC/hMSC donors (donors 5 and 6). (B) After culture of 6 days with rIL-2 in the presence or absence of 
hMAPCs (S:R ratio of 1:3) during the activation phase, purified NK cells were cocultured with K562 leukemia cell line at E:T ratios 
of 50:1 and 25:1 during the effector phase of NK cells. Specific K562 lysis was measured with 51Cr release. Data are expressed as 
mean ± SEM percentage 51Cr release of eight experiments using five different NK cell donors and three different hMAPC donors 
(donors 1, 5, 6).
INTERACTIONS BETWEEN hMAPCs AND NK CELLS 1109
of NK cell proliferation, and mechanism of immuno-
modulation, hMAPCs did not differ in function from 
hMSCs as described in literature. Nevertheless, some dif-
ferences in immunomodulatory action between hMAPCs 
and hMSCs were found compared to literature and from 
own experiments. First of all, the modulatory effects of 
hMAPCs during the rIL-2-induced stimulation phase of 
NK cells in our study were different compared to hMSCs 
in the study by Spaggiari et al. (23). In the latter study, 
coculture of purified NK cells with irradiated hMSCs 
for 6 days in the presence of rIL-2 did not only strongly 
reduce the rIL-2-induced proliferation but also inhibited 
the cytotoxic activity of the purified NK cells. Next, in 
our hands, hMSCs became available from the same donor 
as hMAPCs only for the experiments on rIL-2-induced 
stimulation of PBMC populations. Enrichment of NK 
cells upon rIL-2 stimulation in the PBMC cultures was 
blocked more by hMAPCs than by hMSCs. As a conse-
quence, the subsequent NK potency of these stimulated 
PBMCs was also reduced in the cultures in the presence 
of hMAPCs but less in the presence of hMSCs. Third, 
Rasmusson et al. demonstrated that hMSCs did not influ-
ence the specific K562 lysis of resting NK cells (18), 
whereas hMAPCs in our study reduced the cytotoxic 
function of resting NK cells when cocultured during the 
effector phase.
The fate of hMAPCs after injection into patients is 
not yet understood. In this study, we demonstrated that 
hMAPCs interact with NK cells in vitro. The final out-
come of this interaction in vivo will depend on the inflam-
matory microenvironment both affecting the activation 
state of the NK cells and also the MHC expression on 
hMAPCs. Our data add to the understanding of clinical 
results of currently running trials using adoptive transfer 
of hMAPCs. Further in vivo studies with patients treated 
with hMAPCs should be done to better understand the 
fate and function of hMAPCs as immune-modulating 
stem cell population.
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